Antigen delivery systems

Expert Review of Vaccines

Volumn 3, Issue 4, 2004, Pages 453-462

  Kersten, Gideon ^a   Hirschberg, Hoang ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Delivery system; Formulation; Jet injection; Liposome; Microneddle; Microsphere; Nanosphere; Neddle free

Indexed keywords

ANTIGEN; BACTERIAL ENZYME; BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CANCER TESTIS ANTIGEN; DNA VACCINE; ENTEROTOXIGENIC ESCHERICHIA COLI COLONIZATION FACTOR; ESCHERICHIA COLI ENTEROTOXIN; HELICOBACTER PYLORI UREASE; HEPATITIS A VACCINE; HUMAN PAPILLOMAVIRUS ANTIGEN; INACTIVATED VACCINE; INFLEXAL; INFLUENZA VACCINE; INFLUENZA VIRUS ANTIGEN; INFLUENZA VIRUS HEMAGGLUTININ; ISCOM; LIPID; LIPOSOME; MALARIA ANTIGEN; MICROSPHERE; NEISSERIA MENINGITIDIS PORE PROTEIN A; NIOSOME; NY ESO 1 ANTIGEN; PARASITE ANTIGEN; POLYMER; SHIGELLA FLEXNERI LIPOPOLYSACCHARIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIROSOME; VIRUS ANTIGEN;

ANTIGEN DELIVERY SYSTEM; ANTIGEN PRESENTATION; BELL PALSY; CLINICAL TRIAL; DEVICE; DRUG DELIVERY SYSTEM; FACIAL NERVE PARALYSIS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; JET INJECTION; MOUSE; NEEDLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANTIGENS; DRUG DELIVERY SYSTEMS; HUMANS; ISCOMS; LIPOSOMES; MICROSPHERES; NEEDLES; VEHICLES;

EID: 4043056554     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.453     Document Type: Review

References (83)

1. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. 68(3), 341-344 (2003).
2. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Org. 77(10), 789-800 (1999).
3. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430-445 (2001).
4. Kersten G, Drane D, Pearse M et al. Liposomes and ISCOMs. In: Novel Vaccination Strategies. Wiley-VCH, Weinheim, Germany, 173-196 (2004).
5. Kersten GF, Crommelin DJ. Liposomes and ISCOMs. Vaccine 21(9-10), 915-920 (2003).
6. Arigita C, Kersten GF, Hazendonk T et al. Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes. Vaccine 21(9-10), 950-960 (2003).
7. Krishnan L, Dicaire CJ, Patel GB, Sprott GD. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated and memory responses: comparison to conventional liposomes and alum. Infect. Immun. 68(1), 54-63 (2000).
8. Alving CR, Levine ML, Woodrow GC, Kaper JB, Cobon GS. Liposomes as adjuvants for vaccines. In: New Generation Vaccines. Second edition, revised and expanded. Marcel Dekker, NY, USA, 16, 207-213 (1997).
9. Wedege E, Hoiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66(7), 3223-3231 (1998). Results of a Phase III clinical study with a vesicle-based vaccine.
10. GouldFogerite S, Kheiri MT, Zhang F et al. Targeting immune response induction with cochleate and liposome-based vaccines. Adv. Drug Deliv. Rev. 32(3), 273-287 (1998).
11. Kersten GF, Spiekstra A, Beuvery EC, Crommelin DJ. On the structure of immune-stimulating saponin-lipid complexes (ISCOMs). Biochim. Biophys. Acta 1062(2), 165-171 (1991).
12. Demana PH, Davies NM, Vosgerau U, Rades T. Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method. Int. J. Pharm. 270(1-2), 229-239 (2004).
13. Cleland JL, Powell MF, Lim A et al. Development of a single-shot subunit vaccine for HIV-1. AIDS Res. Hum. Retrovirus 10(Suppl. 2), S21-S26 (1994).
14. Gupta RK, Singh M, O'Hagan DT. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev. 32(3), 225-246 (1998).
15. Kersten GFA, Gander B, Kaufmann SHE. Biodegradable microspheres as vehicles for antigens. In: Concepts in Vaccine Development. Walter de Gruyter, NY, USA, 265-302 (1996).
16. Kersten GFA, Donders D, Akkermans A, Beuvery EC. Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen. Vaccine 14(17-18), 1627-1632 (1996).
17. Weert Mvd, Hennink WE, Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 17(10), 1159-1167 (2000).
18. Johansen P, Tamber H, Merkle HP, Gander B. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. Eur. J. Pharm. Biopharm. 47(3), 193-201 (1999).
19. Zhou S, Liao X, Li X, Deng X, Li H. Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems. J. Control. Release 86(2-3), 195-205 (2003).
20. Jung T, Koneberg R, Hungerer KD, Kissel T. Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock- copolymers: immune response in mice. Int. J. Pharm. 234(1-2), 75-90 (2002).
21. O'Hagan D, Singh M, Ugozzoli M et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNAc vaccines. J. Virol. 75(19), 9037-9043 (2001).
22. Singh M, Briones M, Ott G, O'Hagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc. Natl Acad. Sci. USA 97(2), 811-816 (2000). Demonstrates that potent ADSs do not need to be high-tech devices.
23. Moynihan JS, Blair J, Coombes A, D'Mello F, Howard CR. Enhanced immunogenicity of a hepatitis B virus peptide vaccine using oligosaccharide ester derivative microparticles. Vaccine 20(13-14), 1870-1876 (2002).
24. Arigita C, van den Berg J, Wensink K et al. Immunogenicity of meningococcal PorA formulations encapsulated in biodegradable microspheres. Eur. J. Pharm. Sci. 21(2-3), 131-141 (2004).
25. Davis SS. Nasal vaccines. Adv. Drug Deliv. Rev. 51(1-3), 21-42 (2001).
26. Katial RK, Brandt BL, Moran EE et al. Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect. Immun. 70(2), 702-707 (2002).
27. Gluck U, Gebbers JO, Gluck R. Phase I evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73(9), 7780-7786 (1999).
28. von Hoegen P. Synthetic biomimetic supra molecular biovector (SMBV) particles for nasal vaccine delivery. Adv. Drug Deliv. Rev. 51(1-3), 113-125 (2001).
29. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl J. Med. 350(9), 896-903 (2004). Unexpected link between intranasal vaccination and adverse neurologic (but temporary) effects; possibly caused by the adjuvant.
30. Soane RJ, Frier M, Perkins AC et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 178(1), 55-65 (1999).
31. van der Lubben I, Kersten G, Fretz MM et al. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21(13-14), 1400-1408 (2003).
32. Vila A, Sanchez A, Janes K et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm. 57(1), 123-131 (2004).
33. Giuliani MM, Del Giudice G, Giannelli V et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187(7), 1123-1132 (1998).
34. Baudner BC, Giuliani MM, Verhoef JC et al. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21(25-26), 3837-3844 (2003).
35. Iqbal M, Lin W, Jabbal-Gill I et al. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21(13-14), 1478-1485 (2003).
36. Alpar HO, Almeida AJA, Brown MRW. Microsphere absorption by the nasal mucosa of the rat. J. Drug Target. 2(2), 147-149 (1994).
37. Cahill ES, O'Hagan DT, Illum L et al. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous hemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 13(5), 455-462 (1995).
38. Kunisawa J, Okudaira A, Tsutusmi Y et al. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine 19(4-5), 589-594 (2000).
39. Hu KF, Lovgren Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Del. Rev. 51(1-3), 149-159 (2001).
40. de Haan A, Geerligs HJ, Huchshorn JP et al. Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13(2), 155-162 (1995).
41. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev. 14(2), 430-445 (2001).
42. Clark MA, Blair H, Liang L et al. Targeting polymerized liposome vaccine carriers to intestinal M cells. Vaccine 20(1-2), 208-217 (2001).
43. Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol. 6(1), 23-32 (2004).
44. Chen HM, Torchilin V, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res. 13(9), 1378-1383 (1996).
45. Prokop A, Kozlov E, Newman GW, Newman MJ. Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application. Biotechnol. Bioeng. 78(4), 459-466 (2002).
46. Kim B, Bowersock T, Griebel P et al. Mucosal immune responses following oral immunization with rotavirus antigens encapsulated in alginate microspheres. J. Control. Release 85(1-3), 191-202 (2002).
47. Yeh MK, Liu YT, Chen JL, Chiang CH. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles. J. Control. Release 82(2-3), 237-247 (2002).
48. van der Lubben I, van Opdorp FA, Hengeveld MR et al. Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model. J. Drug Target. 10(6), 449-456 (2002).
49. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68(4), 2135-2141 (2000).
50. Bumann D, Hueck C, Aebischer T, Meyer TF. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol. Med. Microbiol. 27(4), 357-364 (2000).
51. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18(5-6), 449-459 (1999).
52. Lee MH, Roussel Y, Wilks M, Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 19(28-29), 3927-3935 (2001).
53. Nouaille S, Ribeiro LA, Miyoshi A et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet. Mol. Res. 2(1), 102-111 (2003).
54. Walmsley AM, Arntzen CJ. Plant cell factories and mucosal vaccines. Curr. Opin. Biotechnol. 14(2), 145-150 (2003).
55. Prausnitz MR. Reversible skin permeabilization for transdermal delivery of macromolecules. Crit. Rev. Ther. Drug Carrier Syst. 14(4), 455-483 (1997).
56. Glenn GM, Taylor DN, Li X et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nature Med. 6(12), 1403-1406 (2000). Demonstrates that it is posible to induce immune responses in humans after vaccination via intact skin.
57. Chen D, Payne LG. Targeting epidermal Langerhans cells by epidermal powder immunization. Cell Res. 12(2), 97-104 (2002).
58. Parent du Chatelet I, Lang J, Schlumberger M et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group. Vaccine 15(4), 449-458 (1997). Systematic comparison of fluid jet-injection and needle injection.
59. Chen D, Maa YF, Haynes JR. Needle-free epidermal powder immunization. Expert Rev. Vaccines. 1(3), 265-276 (2002).
60. + T-cells, T-helper cells and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2000).
61. Epstein JE, Gorak EJ, Charoenvit Y et al. Safety, tolerability and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection and comparison of intramuscular and combination intramuscular/intradermal routes. Hum. Gene Ther. 13(13), 1551-1560 (2002).
62. Williams J, Fox-Leyva L, Chistensen C et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 18(18), 1939-1943 (2000).
63. van de Wijdeven, GG. Development and assessment of mini projectiles as drug carriers. J. Control. Release 85(1-3), 145-162 (2002).
64. McAllister DV, Wang PM, Davis SP et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. Proc. Natl. Acad. Sci. USA 100(24), 13755-13760 (2003). Demonstrates universal applicability of the concept of delivery of high molecular weight materials via microneedles.
65. Matriano JA, Cormier M, Johnson J et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. 19(1), 63-70 (2002).
66. Mikszta JA, Alarcon JB, Brittingham JM et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Med. 8(4), 415-419 (2002)· Demonstrates that 'wiping' the skin with blunt, coated microneedles results in immune responses.
67. Glenn GM, Kenney RT, Ellingsworth LR et al. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2(2), 253-267 (2003).
68. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. Structure of the skin barrier and its modulation by vesicular formulations. Prog. Lipid Res. 42(1), 1-36 (2003).
69. Paul A, Cevc G, Bachhawat BK. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 16(2-3), 188-195 (1998).
70. Fries LF, Gordon DM, Richards RL et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA 89(1), 358-362 (1992).
71. Fries LF, Montemarano AD, Mallett CP et al. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun. 69(7), 4545-4553 (2001).
72. Kaji M, Kaji Y, Kaji M et al. Phase I clinical tests of influenza MDP-virosome vaccine (KD-5382). Vaccine 10(10), 663-667 (1992).
73. Gluck R, Mischler R, Brantschen S et al. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90(6), 2491-2495 (1992).
74. Just M, Berger R, Drechsler H, Brantschen S, Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only 2 weeks. Vaccine 10(11), 737-739 (1992).
75. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet 343(8893), 322-324 (1994).
76. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ. Safety, immunogenicity and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 13(10), 891-893 (1995).
77. Gluck R, Mischler R, Finkel B et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344(8916), 160-163 (1994).
78. Gluck R, Mischler R, Durrer P et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181(3), 1129-1132 (2000).
79. Cebon JS, Davis ID, Parente P et al. A Phase I clinical trial of NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM® adjuvant) in patients with minimal residual disease. Cancer Immun. 3(Suppl. 1), 19 (2003).
80. Frazer IH, Leggatt GJ, Matsumoto K et al. Immunotherapy for HPV associated precancer. Cancer Immun. 3(Suppl. 1), 25 (2003).
81. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A et al. A randomized, double-blind study in young healthy adults comparing cell-mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19(9-10), 1180-1187 (2000).
82. + T-cells, T-helper cells and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2000).
83. Guerena-Burgueno F, Hall ER, Taylor DN et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70(4), 1874-1880 (2002).